Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC

Inclusion Criteria: 1. Patients with stage II, III, and IV epithelial ovarian cancer who can be surgically resected and can provide sufficient tumor tissue samples, including paraffin-embedded (FFPE) blocks or fresh sections of formalin-fixed tissue within six months (approved by the organizer only); 2. 18-70 years old; 3. In the judgment of the researcher, be able to comply with the research protocol; 4. Voluntarily join the study and sign the informed consent; 5. Patients should meet the following hematological indicators: neutrophil count ≥1.5×109 /L; Hemoglobin ≥10.0 g/dL; Platelet count ≥100×109 /L; Total bilirubin ≤2× upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2× upper limit of normal value (ULN); Creatinine clearance ≥60 ml/min; 6. Expected survival ≥ 3 months; 7. The performance status of the Eastern Cancer Cooperation Group (ECOG) was 0 or 1. 8. Postoperative ctDNA MRD test was positive, routine blood index was negative, imaging was negative. Exclusion Criteria: 1. The patient has HIV infection, HBV infection, HCV infection, uncontrolled coronary artery disease or asthma, uncontrolled cerebrovascular disease, or other disease that the investigator considers ineligible; 2. Patients with a history of bone marrow or organ transplantation; 3. People with coagulation disorders; 4. Gastrointestinal bleeding or gastrointestinal bleeding tendency; 5. Subjects with immune deficiency diseases or autoimmune diseases; 6. Patients who have received other immunotherapy within 1 month (such as immunotherapy with checkpoint inhibitors, therapeutic antibodies, immune cell therapy, and immune system modulator therapy); 7. People who may be allergic to immunotherapy; 8. The patient is affected by drug abuse, clinical or psychological or social factors that make informed consent or research implementation affected; 9. Pregnant and lactating women; 10. Patients who are participating in or have participated in other clinical trials within 1 month; 11. Any uncertainty affecting the patient's safety or compliance.